In vitro evaluation of GL331's cancer cell killing and apoptosis- inducing activity in combination with other chemotherapeutic agents

Tze Sing Huang, Chih Hung Shu, Chun Chung Lee, Li Tzong Chen, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

GL331 is a novel podophyllotoxin-derived compound and is more efficacious than its congener VP-16 in killing several types of cancer cells, that has promoted considerable interest in its possibility of clinical use. In this study, we found that the higher cytotoxicity of GL331 in nasopharyngeal carcinoma NPC-TW01 cells was attributed to the elevated ability to induce apoptotic cell death. In addition to evaluation of GL331's single agent activity, the use of GL331 in combination with other established therapeutic agents was also evaluated. We found that GL331-induced cell cycle perturbation occurred upon initial 8-h exposure, and pretreatment of NPC-TW01 cells with GL331 for 8 h significantly interfered with the cytotoxicities of VP-16, cisplatin, 5-fluorouracil and adriamycin. When the schedule of drug administration was reversed, high-toxic concentrations of these agents revealed an antagonistic effect on GL331; however, their low-toxic doses had the additive or even more-than-additive effect on the cytotoxicity induced by GL331 at 0.1 μM or less, but for GL331 concentrations of greater than 1 μM, the effect became less than additive. These data suggest that overlapping mechanisms could be elicited by GL331 and other agents, and additional preclinical studies are needed to determine the optimal dose combination and administration schedule that will enhance, rather than interfere with, the efficacy of GL331 in combination with other anti-cancer agents.

Original languageEnglish
Pages (from-to)79-85
Number of pages7
JournalApoptosis
Volume5
Issue number1
DOIs
Publication statusPublished - Mar 23 2000
Externally publishedYes

Fingerprint

Cells
Apoptosis
Neoplasms
Cytotoxicity
Poisons
Etoposide
Drug Administration Schedule
GL 331
In Vitro Techniques
Podophyllotoxin
Cell death
Fluorouracil
Doxorubicin
Cisplatin
Appointments and Schedules
Cell Cycle
Cell Death
Pharmaceutical Preparations

Keywords

  • Apoptosis
  • Combination chemotherapy
  • GL331
  • VP-16

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Cancer Research

Cite this

In vitro evaluation of GL331's cancer cell killing and apoptosis- inducing activity in combination with other chemotherapeutic agents. / Huang, Tze Sing; Shu, Chih Hung; Lee, Chun Chung; Chen, Li Tzong; Whang-Peng, Jacqueline.

In: Apoptosis, Vol. 5, No. 1, 23.03.2000, p. 79-85.

Research output: Contribution to journalArticle

@article{7fb4eb86ab80423a8795cd1c80ae58f8,
title = "In vitro evaluation of GL331's cancer cell killing and apoptosis- inducing activity in combination with other chemotherapeutic agents",
abstract = "GL331 is a novel podophyllotoxin-derived compound and is more efficacious than its congener VP-16 in killing several types of cancer cells, that has promoted considerable interest in its possibility of clinical use. In this study, we found that the higher cytotoxicity of GL331 in nasopharyngeal carcinoma NPC-TW01 cells was attributed to the elevated ability to induce apoptotic cell death. In addition to evaluation of GL331's single agent activity, the use of GL331 in combination with other established therapeutic agents was also evaluated. We found that GL331-induced cell cycle perturbation occurred upon initial 8-h exposure, and pretreatment of NPC-TW01 cells with GL331 for 8 h significantly interfered with the cytotoxicities of VP-16, cisplatin, 5-fluorouracil and adriamycin. When the schedule of drug administration was reversed, high-toxic concentrations of these agents revealed an antagonistic effect on GL331; however, their low-toxic doses had the additive or even more-than-additive effect on the cytotoxicity induced by GL331 at 0.1 μM or less, but for GL331 concentrations of greater than 1 μM, the effect became less than additive. These data suggest that overlapping mechanisms could be elicited by GL331 and other agents, and additional preclinical studies are needed to determine the optimal dose combination and administration schedule that will enhance, rather than interfere with, the efficacy of GL331 in combination with other anti-cancer agents.",
keywords = "Apoptosis, Combination chemotherapy, GL331, VP-16",
author = "Huang, {Tze Sing} and Shu, {Chih Hung} and Lee, {Chun Chung} and Chen, {Li Tzong} and Jacqueline Whang-Peng",
year = "2000",
month = "3",
day = "23",
doi = "10.1023/A:1009693811093",
language = "English",
volume = "5",
pages = "79--85",
journal = "Apoptosis : an international journal on programmed cell death",
issn = "1360-8185",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - In vitro evaluation of GL331's cancer cell killing and apoptosis- inducing activity in combination with other chemotherapeutic agents

AU - Huang, Tze Sing

AU - Shu, Chih Hung

AU - Lee, Chun Chung

AU - Chen, Li Tzong

AU - Whang-Peng, Jacqueline

PY - 2000/3/23

Y1 - 2000/3/23

N2 - GL331 is a novel podophyllotoxin-derived compound and is more efficacious than its congener VP-16 in killing several types of cancer cells, that has promoted considerable interest in its possibility of clinical use. In this study, we found that the higher cytotoxicity of GL331 in nasopharyngeal carcinoma NPC-TW01 cells was attributed to the elevated ability to induce apoptotic cell death. In addition to evaluation of GL331's single agent activity, the use of GL331 in combination with other established therapeutic agents was also evaluated. We found that GL331-induced cell cycle perturbation occurred upon initial 8-h exposure, and pretreatment of NPC-TW01 cells with GL331 for 8 h significantly interfered with the cytotoxicities of VP-16, cisplatin, 5-fluorouracil and adriamycin. When the schedule of drug administration was reversed, high-toxic concentrations of these agents revealed an antagonistic effect on GL331; however, their low-toxic doses had the additive or even more-than-additive effect on the cytotoxicity induced by GL331 at 0.1 μM or less, but for GL331 concentrations of greater than 1 μM, the effect became less than additive. These data suggest that overlapping mechanisms could be elicited by GL331 and other agents, and additional preclinical studies are needed to determine the optimal dose combination and administration schedule that will enhance, rather than interfere with, the efficacy of GL331 in combination with other anti-cancer agents.

AB - GL331 is a novel podophyllotoxin-derived compound and is more efficacious than its congener VP-16 in killing several types of cancer cells, that has promoted considerable interest in its possibility of clinical use. In this study, we found that the higher cytotoxicity of GL331 in nasopharyngeal carcinoma NPC-TW01 cells was attributed to the elevated ability to induce apoptotic cell death. In addition to evaluation of GL331's single agent activity, the use of GL331 in combination with other established therapeutic agents was also evaluated. We found that GL331-induced cell cycle perturbation occurred upon initial 8-h exposure, and pretreatment of NPC-TW01 cells with GL331 for 8 h significantly interfered with the cytotoxicities of VP-16, cisplatin, 5-fluorouracil and adriamycin. When the schedule of drug administration was reversed, high-toxic concentrations of these agents revealed an antagonistic effect on GL331; however, their low-toxic doses had the additive or even more-than-additive effect on the cytotoxicity induced by GL331 at 0.1 μM or less, but for GL331 concentrations of greater than 1 μM, the effect became less than additive. These data suggest that overlapping mechanisms could be elicited by GL331 and other agents, and additional preclinical studies are needed to determine the optimal dose combination and administration schedule that will enhance, rather than interfere with, the efficacy of GL331 in combination with other anti-cancer agents.

KW - Apoptosis

KW - Combination chemotherapy

KW - GL331

KW - VP-16

UR - http://www.scopus.com/inward/record.url?scp=0034018817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034018817&partnerID=8YFLogxK

U2 - 10.1023/A:1009693811093

DO - 10.1023/A:1009693811093

M3 - Article

C2 - 11227495

AN - SCOPUS:0034018817

VL - 5

SP - 79

EP - 85

JO - Apoptosis : an international journal on programmed cell death

JF - Apoptosis : an international journal on programmed cell death

SN - 1360-8185

IS - 1

ER -